Bladder cancer has been billed by AstraZeneca as a key growth area for its immunotherapy Imfinzi, an ambition that has now been buoyed by the results of the VOLGA trial. VOLGA was conducted in ...
Scouring through corporate communications and broker research isn’t enough Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results